Partager
Prevention of human immunodeficiency virus (HIV) transmission by taking medication, also called pre-exposure prophylaxis (PrEP), is offered to people who want to reduce the risk of becoming infected by this virus during the course of high-risk sexual practices, or needle sharing during drug use. In 2017, the initial evaluation of the emtricitabine + tenofovir combination established that it is a useful option in this setting...
|
Glossary
public body • plasma assay • adherence • funding ...
Questions (True or False?)
1- A systematic review published by the US Preventive ServicesTask Force in 2019 concluded that PrEP is safe during pregnancy.
2- In trials that included persons whose adherence was estimated at less than or equal to 40%, PrEP did not reduce the number of HIV infections.
3- PrEP does not protect drug users against HIV infection.
4- Use of the emtricitabine + tenofovir combination without any other anti-retroviral in a HIV-infected patient carries a risk of developing resistance to these antiretroviral drugs.
|
Pour le texte + glossaire + questions/réponses, téléchargez l'exercice complet.
©Compétence 4 • Octobre 2021
Le texte complet est réservé aux abonné·e·s.
"Take it easy. Pre-exposure prophylaxis for HIV (PrEP) : useful for some high-risk patients"
Compétence 4 • 2021 ; 4 (46) : 314. > Pdf (réservé aux abonnés)
